CellCentric Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CellCentric Ltd - overview
Established
2003
Location
Cambridge, England, UK
Primary Industry
Biotechnology
About
CellCentric Ltd, based in the UK, is focused on developing innovative pharmaceutical therapies, particularly targeting cancer treatment through advanced molecular inhibitors. Founded in 2003 and headquartered in Cambridge, UK, CellCentric Ltd concentrates on the development of pharmaceutical therapies, specifically their lead product, inobrodib. The company was co-founded by Azim Surani, with Will West serving as CEO. In May 2026, CellCentric Limited raised USD 220 million in series D funding led by Venrock, with participation from Fidelity Investments, HBM Partners, Sofinnova Partners, Avego, BrightEdge Ventures, Forbion, Pfizer Inc.
, and RA Capital Management. CellCentric specializes in innovative pharmaceutical therapies, with its core product, inobrodib, a first-in-class small molecule inhibitor. This drug selectively targets the p300/CBP proteins to disrupt cancer cell growth, particularly in treating multiple myeloma. Inobrodib is undergoing clinical trials and is designed for oral administration, aiming to ease the treatment process for patients.
Their clientele consists mainly of healthcare providers and oncology specialists across North America, Europe, and parts of Asia, who are seeking new cancer therapy options. CellCentric's revenue model involves partnerships with research institutions and pharmaceutical companies for the development and commercialization of inobrodib. The revenue anticipated from licensing agreements and future sales hinges on the regulatory approval and market entry of inobrodib. The company will use the May 2026 funding to support registration trials, continue development of its drug candidate, and advance studies across multiple treatment settings.
Current Investors
5Y Capital, Morningside, BrightEdge Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.cellcentric.com
Verticals
Manufacturing
Company Stage
Series D
Total Amount Raised
Subscriber access only
CellCentric Ltd - financials
| Fiscal Year Ended | May 31, 2010 | May 31, 2011 | May 31, 2012 | May 31, 2013 | May 31, 2014 | May 31, 2015 | May 31, 2016 | May 31, 2017 | May 31, 2018 | May 31, 2019 | May 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,000,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | (100.0%) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (799,345) | (1,439,508) | (2,103,890) | (1,512,317) | - | - | - | - | - | - | - | (9,289,578) | - | - | - |
| Operating Income (USD) | (805,776) | (1,443,889) | (2,105,893) | (1,514,033) | - | - | - | - | - | - | - | (9,289,578) | - | - | - |
| Operating Margin | (80.6%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | (79.9%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (614,044) | (1,235,413) | (1,773,648) | (1,387,739) | - | - | - | - | - | - | - | (9,281,892) | - | - | - |
| % Net Margin | (61.4%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CellCentric Ltd - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.